These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 15251318

  • 1. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A, Moreso FJ, Seron D, Gil-Vernet S, Cruzado JM, Castelao AM, Grinyó JM.
    Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
    [Abstract] [Full Text] [Related]

  • 2. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
    Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B.
    Transplantation; 2008 Dec 27; 86(12):1732-7. PubMed ID: 19104413
    [Abstract] [Full Text] [Related]

  • 3. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 27; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 4. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P.
    Transpl Int; 2002 Nov 27; 15(11):550-5. PubMed ID: 12461659
    [Abstract] [Full Text] [Related]

  • 5. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM, Canafax DM, Gillingham KJ, Humar A, Pandian K, Kerr SR, Najarian JS, Matas AJ.
    Clin Transplant; 1997 Dec 27; 11(6):552-7. PubMed ID: 9408683
    [Abstract] [Full Text] [Related]

  • 6. Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience.
    Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M.
    Saudi J Kidney Dis Transpl; 2008 Jul 27; 19(4):564-70. PubMed ID: 18580014
    [Abstract] [Full Text] [Related]

  • 7. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
    Giral M, Taddei C, Nguyen JM, Dantal J, Hourmant M, Cantarovich D, Blancho G, Ancelet D, Soulillou JP.
    Clin Transpl; 1996 Jul 27; ():257-64. PubMed ID: 9286575
    [Abstract] [Full Text] [Related]

  • 8. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X, Johnston A.
    Transplant Proc; 2004 Jun 27; 36(5):1321-6. PubMed ID: 15251323
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 10. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M, Szepietowski T, Szewczyk Z, Szydłowski Z.
    Arch Immunol Ther Exp (Warsz); 1992 May 27; 40(2):163-8. PubMed ID: 1299176
    [Abstract] [Full Text] [Related]

  • 11. Graft outcome in cadaver renal transplants treated with full-dose cyclosporine induction without antibody, irrespective of graft function.
    Douzdjian V, Bhaskar S, Baliga PK, Rajagopalan PR.
    Clin Transplant; 1997 Aug 27; 11(4):294-8. PubMed ID: 9267718
    [Abstract] [Full Text] [Related]

  • 12. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
    Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL.
    Clin Transplant; 1994 Aug 27; 8(4):388-95. PubMed ID: 7949545
    [Abstract] [Full Text] [Related]

  • 13. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N, Rodger RS, McMillan MA, Junor BJ.
    Transplantation; 2007 Mar 15; 83(5):582-7. PubMed ID: 17353778
    [Abstract] [Full Text] [Related]

  • 14. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr 15; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 15. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 16. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 15; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 17. [Acute rejection in cadaveric renal transplantation under cyclosporine based therapy. Analysis of the risk factors and its influence on chronic dysfunction].
    Mota A.
    Acta Med Port; 2004 Jan 15; 17(1):8-14. PubMed ID: 15636737
    [Abstract] [Full Text] [Related]

  • 18. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
    Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M.
    Transplant Proc; 2008 Jan 15; 40(6):1858-61. PubMed ID: 18675070
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 15; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 20. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation.
    Opelz G, Döhler B, Collaborative Transplant Study.
    Transplantation; 2009 Mar 27; 87(6):795-802. PubMed ID: 19300179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.